Pharma as a sector has been on a tear for last couple of quarters and seems to be picking up good pace.
Lupin Weekly Chart. It made a new ATH lately after 9 years. If one notices, PAT was 2444 in FY15. Current TTM PAT is yet to cross FY15 PAT but stock has already moved higher. What a roller coaster in margins it has had. From 28% peak EBITDA to 1% in FY22 and now back to 20% for TTM.
Management guided to get back to 23%-24% EBITDA levels in medium term along with healthy topline growth. US, Non-US, India markets – all are doing well and company has a decent pipeline of products to be rolled out in next quarters.
Disc: trading position
| Subscribe To Our Free Newsletter |
